Med Business World

Your source for healthcare business

Elise Solberg

PharmaLogic announces opening of radiopharmaceutical production facility in New York City

PharmaLogic Holdings Corp., (“PharmaLogic” or “the company”), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, celebrates the opening of its radiopharmaceutical production and research facility in the Bronx, New York. Acquired in 2022, the facility has undergone…

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

WAT Medical Enterprise achieves a major milestone: HeadaTerm 2 receives the OTC clearance from the U.S. Food and Drug Administration (FDA), making it one of the only wearable anti-migraine devices that is available without a prescription in the U.S. Using neuromodulation…

First Patient Treated in Phase 2 GvHD Trial

Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).  CYP-001 is…

Father of Exactech Employee Receives First Ankle Replacement Using Activit-E™ Polyethylene

Exactech Quality Control Manager Wesley Garrett experienced a full circle moment in both his professional and personal life when his father received an Activit-E™ polyethylene insert after following the company’s polyethylene initiatives for six years.  In 2018, Garrett was hired as an intern to…

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

 IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in…

Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the Company’s first indication-specific drug registration for Trunerox™ issued by…

Sudden Cardiac Arrest Survivor Dr. LaNysha Adams Launches ME POWER Audiobook, Defying Odds in American Heart Month Celebration

Award-winning author and founder of Edlinguist Solutions LaNysha Adams, Ph.D. is set to captivate audiences nationwide as she launches the audiobook version of her acclaimed bestseller, ME POWER (ISBN: 979-8885045698) during American Heart Month. Dr. Adams, a 7-time award-winning author, mother of…

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of advanced malignant tumors. The…

Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy

On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. KGX101 is a recombinant IL-12 Fc fusion protein designed for intravenous injection. The KGX101 clinical trials will…

IEHP’s 2023 Future of Health Summit sheds light on mental health

A deep dive into the mental health crisis was the focus of the 2023 Future of Health Summit hosted by Inland Empire Health Plan (IEHP). On. Oct. 13, health care professionals across the region gathered at the not-for-profit health organization’s Rancho Cucamonga headquarters….